Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma

NCT01774344 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

573

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Hepatocellular

Interventions

DRUG: Regorafenib (Stivarga, BAY73-4506)
DRUG: Placebo

Sponsor

Bayer